Human Vaccines & Immunotherapeutics (Jan 2023)

Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors

  • Laura L. Hammitt,
  • Dean Quinn,
  • Ewa Janczewska,
  • Francisco J. Pasquel,
  • Richard Tytus,
  • K. Rajender Reddy,
  • Katia Abarca,
  • Ilsiyar M. Khaertynova,
  • Ron Dagan,
  • Rachel Dawson,
  • Jennifer McCauley,
  • Tulin Shekar,
  • Wei Fu,
  • Alison Pedley,
  • Tina Sterling,
  • Gretchen Tamms,
  • Luwy Musey,
  • Ulrike K. Buchwald

DOI
https://doi.org/10.1080/21645515.2023.2177066
Journal volume & issue
Vol. 19, no. 1

Abstract

Read online

Immunocompetent adults with certain medical and behavioral factors are at increased risk of pneumococcal disease. In some countries, sequential vaccination with 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for at-risk adults. This subgroup analysis from a phase 3 study evaluated the safety, tolerability, and immunogenicity of sequential administration of either V114 (a 15-valent PCV containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F) or PCV13, followed 6 months later by PPSV23, in immunocompetent adults 18–49 years of age with pre-defined risk factors for pneumococcal disease. Safety and immunogenicity post-vaccination were analyzed by type and baseline number of risk factors for pneumococcal disease (1 and ≥2 risk factors). This analysis included 1,131 participants randomized 3:1 to receive either V114 or PCV13, followed by PPSV23. The majority (73.1%) of participants had at least one risk factor. Safety and tolerability profiles of V114 and PCV13 were similar across risk factor groups. V114 administered either alone or sequentially with PPSV23 6 months later was immunogenic for all 15 serotypes, including those not contained in PCV13, regardless of the number of baseline risk factors. V114 has the potential to broaden serotype coverage for at-risk adults.

Keywords